Targeting neutrophils for host-directed therapy to treat tuberculosis
Autor: | Gareth Griffiths, Tobias Dallenga, Lara Linnemann, Urska Repnik, Ulrich E. Schaible, Bhesh R. Paudyal |
---|---|
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Microbiology (medical) medicine.medical_specialty Tuberculosis Neutrophils medicine.drug_class Antibiotics Antitubercular Agents Microbiology Mycobacterium tuberculosis 03 medical and health sciences 0302 clinical medicine medicine Animals Humans Intensive care medicine Adverse effect biology business.industry General Medicine biology.organism_classification medicine.disease Lipids 030104 developmental biology Infectious Diseases Neutrophil Infiltration 030220 oncology & carcinogenesis Immunology Treatment time business Treatment need |
Zdroj: | International Journal of Medical Microbiology. 308:142-147 |
ISSN: | 1438-4221 |
Popis: | M. tuberculosis is one of the prime killers from infectious diseases worldwide. Infections with multidrug-resistant variants counting for almost half a million new cases per year are steadily on the rise. Tuberculosis caused by extensively drug-resistant variants that are even resistant against newly developed or last resort antibiotics have to be considered untreaTable Susceptible tuberculosis already requires a six-months combinational therapy which requires further prolongation to treat drug-resistant infections. Such long treatment schedules are often accompanied by serious adverse effects causing patients to stop therapy. To tackle the global tuberculosis emergency, novel approaches for treatment need to be urgently explored. Host-directed therapies that target components of the defense system represent such a novel approach. In this review, we put a spotlight on neutrophils and neutrophil-associated effectors as promising targets for adjunct host-directed therapies to improve antibiotic efficacy and reduce both, treatment time and long-term pathological sequelae. |
Databáze: | OpenAIRE |
Externí odkaz: |